Approved & therapeutic
PT-141
Bremelanotide
A peptide that works through the nervous system (not the vascular system) to address sexual dysfunction. Acts on melanocortin receptors in the brain.
Also known as: Vyleesi, PT141
- Status
- PT-141 is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- ~2.7 hours
- How it's taken
- Subcutaneous injection or nasal spray
- Mechanism
- Melanocortin receptor
- Pathways
- Melanocortin
How PT-141 works
Activates melanocortin-4 receptors (MC4R) in the brain, which are involved in sexual arousal and desire. Unlike vascular-based treatments, it works through your central nervous system.
What research has looked at
- Improved sexual desire and arousal
- Works for both men and women
- Does not require vascular function
- Fast onset of action
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea (most common)
- Flushing
- Headache
- Temporary increase in blood pressure
- Skin darkening with repeated use
- Injection site reactions
Sources
- FDA approved-drug listing for bremelanotide · U.S. Food & Drug Administration
- DailyMed prescribing information for bremelanotide · NIH · DailyMed
- PubMed research on bremelanotide PT-141 HSDD · NIH · National Library of Medicine
- DrugBank record for bremelanotide · DrugBank
Track PT-141 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
PT-141 FAQ
What is PT-141?
A peptide that works through the nervous system (not the vascular system) to address sexual dysfunction. Acts on melanocortin receptors in the brain.
How does PT-141 work?
Activates melanocortin-4 receptors (MC4R) in the brain, which are involved in sexual arousal and desire. Unlike vascular-based treatments, it works through your central nervous system.
Is PT-141 FDA approved?
Yes. PT-141 is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of PT-141?
Reported half-life: ~2.7 hours.
How is PT-141 taken?
Subcutaneous injection or nasal spray.
What side effects have been reported with PT-141?
Reported in the sources: Nausea (most common); Flushing; Headache; Temporary increase in blood pressure; Skin darkening with repeated use; Injection site reactions.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.